GLP-1 analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
== Pressure field in a Leidenfrost droplet == The equation for the pressure field in the vapor region between the droplet and the solid surface can be solved for using the standard momentum and continuity equations using a Boundary layer model. In this model for the sake of simplicity in solving, a linear temperature profile and a parabolic velocity profile are assumed within the vapor phase. The heat transfer within the vapor phase is assumed to be through conduction. With these approximations, the Navier–Stokes equations can be solved to get the pressure field.
=== Next-generation matrix for compartmental models === In mathematical modelling of infectious disease, the dynamics of spreading is usually described through a set of non-linear ordinary differential equations (ODE). So there is always
Stephen Standfast is designated as his successor. 12 August – Green Party co-leader Chlöe Swarbrick is banned from Parliament for one week after criticising government MPs during a debate on the recognition of Palestine. 15 August: The Supreme Court of New Zealand rules that the Family Court used the wrong legal test to lock up a 20 year old autistic man for 20 years. The Supreme Court rules that riverbeds can be included in Māori customary marine title claims in the eastern Bay of Plenty. KiwiRail agrees to pay HD Hyundai Mipo a settlement of NZ$144 million for the New Zealand Government's 2023 cancellation of the Project iRex ferries. 16 August: Palestinian solidarity protests calling for an end to the Gaza war and sanctions against Israel are held in 20 cities and towns. Staff at Spring Hill Corrections facility quell a riot involving 11 prisoners. About 100 environmental protesters confront Resources Management Minister Shane Jones during his visit to Whangārei. The protesters were opposed to two fast-track projects including the construction of a marina in Waipiro Bay and proposed offshore sand mining in Bream Bay. Multiple trans-Tasman flights are disrupted by a technical fault in Airways New Zealand's main oceanic air control system. 18 August: KiwiRail's Interislander ferry Aratere is retired. Building and Construction Minister Chris Penk announces that the Government will introduce legislation to overhaul the building consent system.
It has been found that the addition of nanomaterials in bulk materials substantially increases their adhesive capabilities by increasing their strength through various bonding mechanisms. Nanomaterials dimension approaches zero, which means that the fraction of the particle's surface to overall atoms increases. Along with surface effects, the movement of nanoparticles also plays a role in dictating their mechanical properties such as shearing capabilities. The movement of particles can be observed under TEM. For example, the movement behavior of MoS2 nanoparticles dynamic contact was directly observed in situ which led to the conclusion that fullerenes can shear via rolling or sliding. However, observing these properties is again a very complicated process due to multiple contributing factors. Applications specific to Mechanical Properties:
Sources: en.wikipedia.org
== Permeability barriers and detoxification == That the exact compounds an organism is exposed to will be largely unpredictable, and may differ widely over time, is a major characteristic of xenobiotic toxic stress. The major challenge faced by xenobiotic detoxification systems is that they must be able to remove the almost-limitless number of xenobiotic compounds from the complex mixture of chemicals involved in normal metabolism. The solution that has evolved to address this problem is an elegant combination of physical barriers and low-specificity enzymatic systems. All organisms use cell membranes as hydrophobic permeability barriers to control access to their internal environment. Polar compounds cannot diffuse across these cell membranes, and the uptake of useful molecules is mediated through transport proteins that specifically select substrates from the extracellular mixture. This selective uptake means that most hydrophilic molecules cannot enter cells, since they are not recognised by any specific transporters. In contrast, the diffusion of hydrophobic compounds across these barriers cannot be controlled, and organisms, therefore, cannot exclude lipid-soluble xenobiotics using membrane barriers. However, the existence of a permeability barrier means that organisms were able to evolve detoxification systems that exploit the hydrophobicity common to membrane-permeable xenobiotics. These systems therefore solve the specificity problem by possessing such broad substrate specificities that they metabolise almost any non-polar compound.
== Further reading == Foreman, John C.; Johansen, Torben; Gibb, Alasdair J., eds. (2010). Textbook of Receptor Pharmacology. doi:10.1201/9781420052558. ISBN 978-0-429-14730-2. Brunton L (2011). Brunton LL, Chabner B, Knollmann BC (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12 ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8. Whalen K (2014). Lippincott Illustrated Reviews: Pharmacology.
=== Thermochemistry === L. K. Doraiswamy, 2005, "Estimation of properties of organic compounds (Ch. 3)," pp. 36–51, 118-124 (refs.), in Organic Synthesis Engineering, Oxford, Oxon, ENG:Oxford University Press, ISBN 0198025696, accessed 22 June 2015. (This book chapter surveys a very wide range of physical properties and their estimation, including the narrow list of thermochemical properties appearing in the June 2015 WP article, placing the Benson et al. method alongside many other methods. L. K. Doraiswamy is Anson Marston Distinguished Professor of Engineering at Iowa State University.) Irikura, Karl K.; Frurip, David J. (1998). "Computational Thermochemistry". In Irikura, Karl K.; Frurip, David J. (eds.). Computational Thermochemistry: Prediction and Estimation of Molecular Thermodynamics. ACS Symposium Series. Vol. 677. American Chemical Society. pp. 2–18. doi:10.1021/bk-1998-0677.ch001. ISBN 978-0-8412-3533-5.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.